Latest Venous ulcer Stories
ROCKVILLE, Md., Nov. 24, 2010 /PRNewswire/ -- Glycotex, Inc., a clinical stage biopharmaceutical company, announced today that it has been awarded a cash grant totaling $244,479 under the U.S. Government's Qualifying Therapeutic Discovery Project (QTDP) program.
ADDISON, Texas, Nov. 10, 2010 /PRNewswire/ -- ULURU Inc.
CANTON, Mass., Sept. 28 /PRNewswire/ -- Organogenesis, Inc. announced that its ApligrafÂ® bilayered living cellular construct has been approved for the treatment of diabetic foot ulcers and other chronic wounds by the Saudi Food and Drug Authority (SFDA) of the Kingdom of Saudi Arabia.
ZUG, Switzerland and CANTON, Mass., May 26 /PRNewswire/ -- Organogenesis Switzerland GmbH will sponsor a symposium on ApligrafÂ®, a bilayered living cellular construct for the treatment of chronic wounds and soft tissue repair, at the upcoming European Wound Management Association (EWMA) conference.
SAN DIEGO, May 25 /PRNewswire/ -- CoDa Therapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of therapeutics for wound care and tissue repair, today announced positive results from its Phase 2 NOVEL Study of NEXAGONÂ® in patients with chronic venous leg ulcers.
ADDISON, Texas, April 8 /PRNewswire-FirstCall/ --ULURU Inc. (NYSE Amex: ULU) announced today that the Company will be presenting clinical data at the 2010 American Professional Wound Care Association(APWCA) National Conference in Philadelphia, PA April 8-11, 2010.
ADDISON, Texas, March 23 /PRNewswire-FirstCall/ -- ULURU Inc. (NYSE Amex: ULU) announced that it sponsored a Wound Dressing Workshop at the 2010 Diabetic Foot Global Conference.
BOSTON, Feb. 18 /PRNewswire/ -- TEI Biosciences Inc. announced today that its PriMatrix(TM) Dermal Repair Scaffold has been awarded the coveted American Podiatric Medical Association's (APMA) Seal of Approval.
ROCKVILLE, Md., Feb. 11 /PRNewswire/ -- Glycotex, Inc. today announced the expansion of its patent portfolio in Advanced Wound Healing for its product candidate GLYC-101 currently in clinical phase 2 in the United States. On January 19, 2010 US Patent No.